Mon05202019

Robins Global News & Noticias



  • Shipping Advice
    Shipping Advice
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting


NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that two of the Company’s abstracts on its lead asset, Plinabulin, have been accepted for publication in the Proceedings of this year’s ASCO Annual Meeting. The data, derived from BeyondSpring’s Phase 2 Study 106, provides a strong rationale for the Plinabulin Neulasta (pegfilgrastim) combination for the prevention of chemotherapy-induced neutropenia (CIN) for improved CIN control. Additionally, the Plinabulin Neulasta combination nearly eliminated patients’ treatment-related bone pain. Study 106 Phase 2 included breast cancer patients receiving TAC (docetaxel, doxorubicin, cyclophosphamide) which has risk for febrile neutropenia.
BeyondSpring’s first abstract (No. e12030), “Comparison of 6mg Pegfilgrastim, Plinabulin and the Combination for CIN Prevention: Rationale for the Combination,” evaluates whether combining Plinabulin with Neulasta, would protect patients against CIN throughout the entire chemotherapy cycle. The two agents have different mechanisms of action, with Plinabulin predominantly protective in the first week of the cycle, and Neulasta predominantly protective in the second week of the cycle. Protection was measured by evaluating the absolute neutrophil count (ANC). The data shows that Plinabulin, when added to the standard dose of Neulasta, offered CIN protection throughout the entire cycle, something that could not be achieved by each of these agents alone. The addition of Plinabulin to Neulasta, almost completely eliminated the Neulasta-induced bone pain, reducing its incidence of at least 1 day of bone-pain from 95 percent (with the standard dose of Neulasta) to 6 percent (with the Plinabulin-Neulasta combination) (p < 0.0001).BeyondSpring’s second abstract (No. e12017), “Plinabulin Combined with Half Dose (3mg) Pegfilgrastim, Compared with Full Dose (6mg) Pegfilgrastim Alone for CIN: Neutrophil, Bone Pain and Immunosuppressive Effects,” compared patients who received a combination of Plinabulin with a half dose of Neulasta to patients who received a full dose of Neulasta alone to test the effects on CIN, bone pain and the immune-suppressive profile. The data highlights that a half dose of Neulasta, combined with Plinabulin, is equally effective against CIN as a full dose of Neulasta alone (demonstrating a strong neutropenia benefit). In addition, the combination therapy offered significantly lower levels of bone pain for patients, as well, along...


Posted: 2019-05-16 12:01:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA

Thu, 16 May 2019 09:00:00 GMT

Incyte Corporation INCY, +2.55% announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) ...

BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting

Thu, 16 May 2019 06:01:00 GMT

BeyondSpring's Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting Adding Plinabulin to Neulasta Offers Better Protection ...

Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

Thu, 16 May 2019 05:01:00 GMT

The two Clovis Oncology-sponsored abstracts accepted for presentation at the 2019 ASCO Annual Meeting comprise: Abstract 5031 (Poster Board #143) - Genomic characteristics of deleterious BRCA1 and ...

Janssen to Present Data from Robust Oncology Portfolio and Pipeline at the 2019 ASCO Annual Meeting, Including Best of ASCO Selections

Wed, 15 May 2019 14:27:00 GMT

RARITAN, N.J., May 15, 2019 /PRNewswire/ -- The Janssen ... at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4. More than 30 company-sponsored ...

Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting

Wed, 15 May 2019 14:00:00 GMT

SAN FRANCISCO, May 15, 2019 /PRNewswire/ -- Nektar Therapeutics NKTR, +2.58% today announced five abstracts accepted for presentation at the 55 [th] Annual Meeting of the American Society of Clinical ...

Related Bing Web Search

Incyte Announces Abstracts Accepted for Presentation at ...

(Fri, 17 May 2019 09:43:00 GMT)

Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA Business Wire WILMINGTON, Del. -- May 16, 2019 Incyte Corporation (Nasdaq:INCY ...

Incyte Announces Abstracts Accepted for Presentation at ...

(Thu, 16 May 2019 11:53:00 GMT)

Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA ... 2019 American Society of Clinical Oncology ... Abstracts accepted for ...

Incyte Announces Abstracts Accepted for Presentation at ...

(Fri, 17 May 2019 06:37:00 GMT)

Incyte Corporation announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology Annual Meeting, to ...

ASCO Meetings

(Thu, 16 May 2019 09:30:00 GMT)

If a first author chooses to withdraw their abstract, he/she must send an email to abstracts@asco.org by Sunday, April 7, 2019. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.

Incyte Announces Abstracts Accepted for Presentation at ...

(Thu, 16 May 2019 17:01:00 GMT)

Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA ... 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held ...

ASCO Meetings

(Thu, 16 May 2019 15:42:00 GMT)

Note: Only those abstracts to be released on site at the 2019 ASCO Annual Meeting will be designated as Late-Breaking Abstracts (LBAs), including Plenary abstracts. LBAs will be publicly released on a rolling basis throughout the 2019 ASCO Annual Meeting. The complete embargo dates and public release schedule for LBAs is as follows:

Incyte Announces Abstracts Accepted for Presentation at ...

(Fri, 17 May 2019 00:32:00 GMT)

WILMINGTON, Del.--(BUSINESS WIRE)--May 16, 2019-- Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24 th Congress of the European Hematology Association (EHA), to be ...

Nektar Therapeutics Announces Five Accepted Abstracts at ...

(Thu, 16 May 2019 01:16:00 GMT)

SAN FRANCISCO, May 15, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 31 to June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.

ASCO Abstracts

(Thu, 16 May 2019 03:18:00 GMT)

2019 ASCO Annual Meeting Abstracts. The 2019 ASCO Annual Meeting abstracts will be published on this website on May 15th, 2019 at 5:00 PM (EST). To view previously released abstracts please visit meetinglibrary.asco.org.

Clovis Oncology Announces Presentations at 2019 ASCO ...

(Fri, 17 May 2019 19:01:00 GMT)

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data for Rubraca ® (rucaparib) and ongoing studies in multiple tumor types will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.. The accepted abstracts summarize clinical trials in which Rubraca is being evaluated as a single agent ...

Related News Story Videos From Youtube

The Power and Promise of Cancer Research: Presented at ASCO Annual Meeting 2018


Related Videos On: The Power and Promise of Cancer Research: Presented at ASCO Annual Meeting 2018


American Society of Clinical Oncology Update 2017


Related Videos On: American Society of Clinical Oncology Update 2017


GI ASCO 2019 Updates – January 2019 Webinar


Related Videos On: GI ASCO 2019 Updates – January 2019 Webinar


Dr. Yantiss interview - 2019 Annual Meeting abstract submissions


Related Videos On: Dr. Yantiss interview - 2019 Annual Meeting abstract submissions


What Cancer Patients Should Know: Latest Immunotherapy News from ASCO 2018


Related Videos On: What Cancer Patients Should Know: Latest Immunotherapy News from ASCO 2018






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.